Li Z, Cestari DM, Fortin E (2018) Thyroid eye disease: what is new to know?[J]. Curr Opin Ophthalmol 29(6):528–534. https://doi.org/10.1097/ICU.0000000000000529

Article  PubMed  Google Scholar 

Cockerham KP, Padnick-Silver L, Stuertz N et al (2021) Quality of life in patients with chronic thyroid eye disease in the United States[J]. Ophthalmol Ther 10(4):975–987. https://doi.org/10.1007/s40123-021-00385-8

Article  PubMed  Google Scholar 

Burch HBB, Perros P, Bednarczuk T et al (2022) Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association[J]. Thyroid 32(12):1439–1470. https://doi.org/10.1089/thy.2022.0251

Article  PubMed  Google Scholar 

Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy[J]. Eur J Endocrinol 185(4):G43–G67. https://doi.org/10.1530/EJE-21-0479

Article  CAS  PubMed  Google Scholar 

Ahn HY, Lee JK (2020) Intravenous glucocorticoid treatment for Korean graves’ ophthalmopathy patients[J]. J Korean Med Sci 35(23):e177. https://doi.org/10.3346/jkms.2020.35.e177

Article  CAS  PubMed  Google Scholar 

Smith TJ, Bartalena L (2019) Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?[J]. Eur J Endocrinol 181(5):D27–D43. https://doi.org/10.1530/EJE-19-0389

Article  CAS  PubMed  Google Scholar 

Kruschke JK (2021) Bayesian analysis reporting guidelines[J]. Nat Hum Behav 5(10):1282–1291. https://doi.org/10.1038/s41562-021-01177-7

Article  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/M14-2385

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Article  PubMed  Google Scholar 

Puhan MA, Schünemann HJ, Murad MH et al (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis[J]. BMJ 349:g5630. https://doi.org/10.1136/bmj.g5630

Article  PubMed  Google Scholar 

Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med 382(4):341–352. https://doi.org/10.1056/NEJMoa1910434

Article  CAS  PubMed  Google Scholar 

Kahaly GJ, Riedl M, König J et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial[J]. Lancet Diabetes Endocrinol 6(4):287–298. https://doi.org/10.1016/S2213-8587(18)30020-2

Article  CAS  PubMed  Google Scholar 

Lanzolla G, Sabini E, Leo M et al (2021) Statins for graves’ orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial[J]. Lancet Diabetes Endocrinol 9(11):733–742. https://doi.org/10.1016/S2213-8587(21)00238-2

Article  CAS  PubMed  Google Scholar 

Li L, Xue J, Guan L et al (2023) Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients[J]. Front Endocrinol 14:1140196. https://doi.org/10.3389/fendo.2023.1140196

Article  Google Scholar 

Salvi M, Vannucchi G, Currò N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: a randomized controlled study[J]. J Clin Endocrinol Metab 100(2):422–431. https://doi.org/10.1210/jc.2014-3014

Article  CAS  PubMed  Google Scholar 

Savino G, Mandarà E, Gari M et al (2015) Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy[J]. Endocrine 48(1):241–247. https://doi.org/10.1007/s12020-014-0283-1

Article  CAS  PubMed  Google Scholar 

Shen L, Ye L, Zhu W et al (2022) Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe graves’ orbitopathy[J]. Eur Thyroid J. https://doi.org/10.1530/ETJ-22-0017

Article  PubMed  Google Scholar 

Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy[J]. N Engl J Med 376(18):1748–1761. https://doi.org/10.1056/NEJMoa1614949

Article  CAS  PubMed  Google Scholar 

Stan MN, Garrity JA, Carranza LB et al (2015) Randomized controlled trial of rituximab in patients with graves’ orbitopathy[J]. J Clin Endocrinol Metab 100(2):432–441. https://doi.org/10.1210/jc.2014-2572

Article  CAS  PubMed  Google Scholar 

van Geest RJ, Sasim IV, Koppeschaar HP et al (2008) Methylprednisolone pulse therapy for patients with moderately severe graves’ orbitopathy: a prospective, randomized, placebo-controlled study[J]. Eur J Endocrinol 158(2):229–237. https://doi.org/10.1530/EJE-07-0558

Article  CAS  PubMed  Google Scholar 

Wang B, Sun J, Hao G et al (2019) (2019) A clinical study on ~(99)Tc-MDP for thyroid-associated ophthalmopathy[J]. Chin J Endemiol 38:922–926

Google Scholar 

Krieger CC, Sui X, Kahaly GJ et al (2022) Inhibition of TSH/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease[J]. J Clin Endocrinol Metab 107(4):e1653–e1660. https://doi.org/10.1210/clinem/dgab824

Article  PubMed  Google Scholar 

Hubschman S, Sojitra B, Ghiam S et al (2024) Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease [J]. Ophthalmic Plastic Reconstr Surg 40(3):270–275. https://doi.org/10.1097/IOP.0000000000002563

Article  Google Scholar 

Hwang CJ, Rebollo NP, Mechels KB et al (2024) Reactivation after teprotumumab treatment for active thyroid eye disease[J]. Am J Ophthalmol 263:152–159. https://doi.org/10.1016/j.ajo.2023.12.001

Article  CAS  PubMed  Google Scholar 

Yan SX, Wang Y, Peng GJ et al (2011) Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with graves’ ophthalmopathy[J]. Nucl Med Commun 32(2):142–146. https://doi.org/10.1097/MNM.0b013e32834121cb

Article  CAS  PubMed  Google Scholar 

Naselli A, Moretti D, Regalbuto C et al (2020) Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves’ ophthalmopathy to parenteral corticosteroids[J]. Front Endocrinol (Lausanne) 11:609895. https://doi.org/10.3389/fendo.2020.609895

Article  PubMed  Google Scholar 

Hsu GC, Shih S, Chang F et al (2024) An appraisal of the preventive effect of statins on the development of graves’ ophthalmopathy: a hospital-based cohort study[J]. Ophthalmol Ther 13(6):1499–1511. https://doi.org/10.1007/s40123-024-00930-1

Article  PubMed  Google Scholar 

Chen J, Chen G, Sun H (2021) Intravenous rituximab therapy for active graves’ ophthalmopathy: a meta-analysis[J]. Hormones (Athens) 20(2):279–286. https://doi.org/10.1007/s42000-021-00282-6

Article  PubMed  Google Scholar 

Li H, Yang L, Song Y et al (2022) Comparative effectiveness of different treatment modalities for active, moderate-to-severe graves’ orbitopathy: a systematic review and network meta-analysis[J]. Acta Ophthalmol 100(6):e1189–e1198. https://doi.org/10.1111/aos.15074

Article  PubMed  Google Scholar 

Zhou X, Zhou D, Wang J et al (2020) Treatment strategies for graves’ ophthalmopathy: a network meta-analysis[J]. Br J Ophthalmol 104(4):551–556. https://doi.org/10.1136/bjophthalmol-2018-313697

Article  PubMed  Google Scholar